|
The information is updated the first week of every month - so ... make this a regular stop in your information gathering activities.The following information has been compiled from publicly available sources, StratCom does not assume any responsibility for the accuracy or the authenticity of the information and StratCom cannot be held liable for errors.
Affymetrix, Inc. and Boston University Medical Center have formed a collaboration using Affymetrix GeneChip brand technology to develop a less invasive sample acquisition method and to identify predictive molecular signatures that may enable screening and early detection of lung cancer in at risk individuals. Epigenomics AG has gained access to two new technologies through a licensing agreement with Johns Hopkins University, Baltimore, MD, and an option agreement with Australia's Commonwealth Scientific and Industrial Research Organisation (CSIRO) Division of Molecular Science based in Sydney, for the early detection of solid tumors. These two separate agreements will be used in Epigenomics' development of tests for DNA methylation and its role in disease detection and monitoring. Genomics Collaborative, Inc. and Celera Diagnostics have formed a collaborative agreement to support Celera Diagnostics' efforts to identify genetic patterns associated with rheumatoid arthritis. GCI will provide Celera Diagnostics access to its DNA sample sets associated with rheumatoid arthritis that are found in GCI's Global Repository. Luminex Corporation and Tm Bioscience Corporation have introduced the Universal Array, a microsphere-based product designed for conducting genotyping and other DNA-based experiments in the life sciences and diagnostic markets using Luminex's proprietary xMAP technology. Molecular Devices Corporation has launched its FLIPR Calcium 3 Assay Kit. The kit uses technology licensed exclusively to Molecular Devices by Bayer AG. Cell-based calcium flux assays are considered one of the most important screening techniques used in pharmaceutical drug discovery. TriPath Oncology, Inc. has signed a definitive agreement with AmeriPath, Inc. to commercialize a novel gene expression assay for malignant melanoma. TriPath Oncology will supply AmeriPath with a novel gene-based probe labeled as an analyte specific reagent (ASR) that will be incorporated into an in situ hybridization assay developed at AmeriPath. AmeriPath will initially offer the melanoma assay at its Center for Advanced Diagnostics facility located in Orlando, FL. AmeriPath shall have exclusive rights to the assay for clinical diagnostic testing services subject to certain diligence milestones. VARIAGENICS, INC. has granted a worldwide non-exclusive license relating to its MTHFR (methylenetetrahydrofolate reductase) patent rights to Celera Diagnostics. Celera plans to commercialize products for the detection of MTHFR polymorphisms for applications including assessment of thromboembolic disease risk (including stroke and myocardial infarction). The products are expected to be sold in the form of analyte specific reagents and potentially later as in vitro diagnostic devices. VARIAGENICS retains the rights to develop pharmacogenomic applications in oncology and other disease areas.
Product Developments Worldwide | Research News | Health Care in Canada Information Technology and Healthcare | Molecular Biology | Links
![[HRule Image]](images/div.jpg){kind=small} Send mail to stratcom@pagebleu.com with questions or comments about this web site.Concept and Design Blue Page
Productions Last modified: February 2, 2003 |
![[Page Banner Image]](images/hmole.gif){kind=small}
